rs1085308078
Variant summary
Our verdict is Likely pathogenic. Variant got 7 ACMG points: 7P and 0B. PP3PM2_SupportingPM1_StrongPM5_Supporting
This summary comes from the ClinGen Evidence Repository: The c.1157A>T (p.Glu386Val) variant is harboured in exon 9 of the BMPR2 gene, encoding the functionally relevant catalytic kinase domain and impacts an amino acid indispensable to kinase structure and function (PM1_strong). This variant is absent from gnomAD v2.1.1 (controls) and v4.1 (PM2_supporting). The variant has been reported once in an FPAH subject (PMID:18364108) (PS4 not met). The REVEL prediction algorithm score is 0.99, the AlphaMissense score is 0.996 indicating pathogenicity (PP3_met). PS2 was not assessed due to lack of paternity data. Functional studies have not been conducted for this variant (PS3 not assessed). Four additional likely pathogenic variants (p.Glu386Ala/Gln/Gly/Lys) have been reported at the same position (PMIDs: 18503968, 21801371, 23675998 and 26387786) (PM5_supporting). In summary, this variant meets the criteria to be classified as likely pathogenic for pulmonary arterial hypertension based on the ACMG/AMP criteria applied, as specified by the ClinGen Pulmonary Hypertension VCEP: PM1_strong, PM2_supporting, PM5_supporting, PP3 (VCEP specification version 1.1.0, 1/18/2024). LINK:https://erepo.genome.network/evrepo/ui/classification/CA350341741/MONDO:0015924/125
Frequency
Consequence
NM_001204.7 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 7 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 31
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 31
ClinVar
Submissions by phenotype
Pulmonary arterial hypertension Pathogenic:1
Likely pathogenic, reviewed by expert panel | curation | Clingen Pulmonary Hypertension Variant Curation Expert Panel, ClinGen | Nov 06, 2024 | The c.1157A>T (p.Glu386Val) variant is harboured in exon 9 of the BMPR2 gene, encoding the functionally relevant catalytic kinase domain and impacts an amino acid indispensable to kinase structure and function (PM1_strong). This variant is absent from gnomAD v2.1.1 (controls) and v4.1 (PM2_supporting). The variant has been reported once in an FPAH subject (PMID: 18364108) (PS4 not met). The REVEL prediction algorithm score is 0.99, the AlphaMissense score is 0.996 indicating pathogenicity (PP3_met). PS2 was not assessed due to lack of paternity data. Functional studies have not been conducted for this variant (PS3 not assessed). Four additional likely pathogenic variants (p.Glu386Ala/Gln/Gly/Lys) have been reported at the same position (PMIDs: 18503968, 21801371, 23675998 and 26387786) (PM5_supporting). In summary, this variant meets the criteria to be classified as likely pathogenic for pulmonary arterial hypertension based on the ACMG/AMP criteria applied, as specified by the ClinGen Pulmonary Hypertension VCEP: PM1_strong, PM2_supporting, PM5_supporting, PP3 (VCEP specification version 1.1.0, 1/18/2024). - |
Pulmonary hypertension, primary, 1 Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | Rare Disease Genomics Group, St George's University of London | - | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at